Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions
The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
The relationship between plaque pathology and disease duration was examined in 15 patients with multiple sclerosis who died early in the course of their illness. Myelin-stained sections revealed that most plaques examined in patients who died during the first month of their illness showed evidence of ongoing myelin destruction accompanied by a loss of oligodendrocytes. Plaques containing large numbers of oligodendrocytes were not observed in these patients, but were relatively common in patients who died more than 1 month after clinical onset. Remyelination affecting more than 10% of the plaque area was observed in 3 of 82 plaques in 5 patients who died within 10 weeks of clinical onset, in 38 of 105 plaques in 5 patients who died 3 to 10 months after clinical onset, and in 19 of 92 plaques in 5 patients who died 18 months or longer after clinical onset. The study provides new evidence that both oligodendrocytes and myelin are destroyed in new lesions, that this activity ceases completely in many lesions within a few weeks, and that remyelination frequently ensues following repopulation of the plaque by oligodendrocytes. The findings suggest that new lesions normally remyelinate unless interrupted by recurrent activity and that remyelinated shadow plaques are the outcome of a single previous episode of focal demyelination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For cortical grey matter, this now indicates that oligodendrocyte recruitment and remyelination is an early phenomenon in MS lesion formation that occurs in the immediate post-phagocytic phase when foam cells are still abundant in the demyelinated lesions.56-60”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [57]
In the citing paper
“However, despite remyelination being very efficient at the early stages of the disease, this process gradually fails over time [115,116].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [115]
Citations
Cites
Handbook of clinical neurology
(1986) · Journal of Neuroimmunology · doi:10.1016/0165-5728(86)90030-5 · Cited by 1,849
Lantos, P. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.496 · Cited by 1,152
Walton, J. N. (1976) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(76)90157-x · Cited by 964
Payne, J. P. (1969) · British Journal of Anaesthesia · doi:10.1093/bja/41.4.356 · Cited by 600
Remyelination in multiple sclerosis
Prineas, J. W., & Connell, F. (1979) · Annals of Neurology · doi:10.1002/ana.410050105 · Cited by 454
Self-citationRemyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
ULTRASTRUCTURAL STUDY OF REMYELINATION IN AN EXPERIMENTAL LESION IN ADULT CAT SPINAL CORD
Bunge, M. B., Bunge, R. P., & Ris, H. (1961) · The Journal of Cell Biology · doi:10.1083/jcb.10.1.67 · Cited by 396
Proliferating bipotential glial progenitor cells in adult rat optic nerve
ffrench-Constant, C., & Raff, M. C. (1986) · Nature · doi:10.1038/319499a0 · Cited by 385
Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis
Lassmann, H. (1983) · Schriftenreihe Neurologie / Neurology Series · doi:10.1007/978-3-642-45558-2 · Cited by 296
Pathology of the Nervous System
Krigman, M. R. (1969) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1969.03160150057026 · Cited by 286
Research works printed but not linked: 3
- Schlesinger H, 1909, Zur Frage der akuten multiplen Sklerose und der Enzephalomyelitis disseminata im Kindesalter, Arch Neurol Inst, Wien, 17, 410
- Greenfield JG, 1958, Neuropathology, 441
- Jacob H, 1969, Tissue process in multiple sclerosis and parainfectious and post‐vaccinal encephalomyelitis, Int Arch Allergy Appl Immunol, 36, 22
Cited by
Items 101–200 of 571
Tajouri, L., Mellick, A. S., Ashton, K. J., Tannenberg, A. E. G., Nagra, R. M., Tourtellotte, W. W., & Griffiths, L. R. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.09.008 · Cited by 143
Parratt, J. D., & Prineas, J. W. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510382324 · Cited by 132
Self-citationMultiple Sclerosis Pathology: Evolution of Pathogenetic Concepts
Lassmann, H. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00523.x · Cited by 130
Penderis, J., Shields, S. A., & Franklin, R. J. M. (2003) · Brain · doi:10.1093/brain/awg126 · Cited by 129
“Although remyelination occurs in many acute plaques of multiple sclerosis (Prineas and Connell, 1979; Prineas et al., 1993a; Lassmann et al., 1997), remyelination failure becomes an increasingly prominent feature of the pathology of chronic multiple sclerosis (Prineas et al., 2002).”
BackgroundA safety and pharmacokinetic study of intravenous natalizumab in patients with MS
Sheremata, W. A., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J., & Koller, M. (1999) · Neurology · doi:10.1212/wnl.52.5.1072 · Cited by 128
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Endogenous cell repair of chronic demyelination
Armstrong, R. C., Le, T. Q., Flint, N. C., Vana, A. C., & Zhou, Y.-X. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000205142.08716.7e · Cited by 125
Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis
Lassmann, H., Suchanek, G., & Ozawa, K. (1994) · Annals of Neurology · doi:10.1002/ana.410360713 · Cited by 124
Wolswijk, G. (2003) · Brain · doi:10.1093/brain/awg151 · Cited by 123
“…may be reexpressed or re-directed to the paranodal region during the process of remyelination because short internodes, which are thought to represent newly formed myelin sheaths (Prineas and Connell, 1979; Lassmann, 1983; Prineas et al., 1993), had bands of Caspr immunoreactivity on either ends.”
BackgroundCarroll, W. (1998) · Brain · doi:10.1093/brain/121.2.293 · Cited by 123
Wilson, H., Scolding, N. J., & Raine, C. S. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.04.014 · Cited by 141
“In the early stages of the disease, inflammatory demyelination is associated with remyelination, visualised as Fshadow plaques_ or narrow zones of myelin pallor by light microscopy (Prineas and Connell, 1979; Prineas et al., 1993; Raine et al., 1981; Raine and Wu, 1993).”
Lassmann, H. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01189.x · Cited by 120
Multiple sclerosis: a battle between destruction and repair
McQualter, J. L., & Bernard, C. C. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04232.x · Cited by 129
“There are strong data suggesting that remyelination occurs during the early course of MS and is associated with disease resolution (Prineas et al. 1989, 1993; Raine and Wu 1993; Lucchinetti et al. 2000).”
Transplanted Neural Precursors Enhance Host Brain-Derived Myelin Regeneration
Einstein, O., Friedman‐Levi, Y., Grigoriadis, N., & Ben‐Hur, T. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3364-09.2009 · Cited by 123
Makar, T. K., Bever, C. T., Singh, I. S., Royal, W., Sahu, S. N., Sura, T. P., Sultana, S., Sura, K. T., Patel, N., Dhib-Jalbut, S. S., et al. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.017 · Cited by 117
PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination
Frost, E. E., Nielsen, J. A., Le, T. Q., & Armstrong, R. C. (2003) · Journal of Neurobiology · doi:10.1002/neu.10158 · Cited by 115
“Limited spontaneous remyelination occurs in acute MS lesions, yet recurring myelin damage is not sufficiently repaired (Raine and Wu, 1993; Prineas et al., 1993).”
BackgroundMyelin regulatory factor drives remyelination in multiple sclerosis
Duncan, G. J., Plemel, J. R., Assinck, P., Manesh, S. B., Muir, F. G. W., Hirata, R., Berson, M., Liu, J., Wegner, M., Emery, B., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1741-7 · Cited by 114
The Pathology of MS: New Insights and Potential Clinical Applications
Pittock, S. J., & Lucchinetti, C. F. (2007) · The Neurologist · doi:10.1097/01.nrl.0000253065.31662.37 · Cited by 116
Roles and regulation of microglia activity in multiple sclerosis: insights from animal models
Distéfano‐Gagné, F., Bitarafan, S., Lacroix, S., & Gosselin, D. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00709-6 · Cited by 119
Tepavčević, V., & Lubetzki, C. (2022) · Brain · doi:10.1093/brain/awac307 · Cited by 108
Chiang, C. S., Powell, H. C., Gold, L. H., Samimi, A., & Campbell, I. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118574 · Cited by 112
Imaging outcomes for trials of remyelination in multiple sclerosis
Mallik, S., Samson, R. S., Wheeler-Kingshott, C. A. M., & Miller, D. H. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307650 · Cited by 111
Oligodendrocytes and Microglia: Key Players in Myelin Development, Damage and Repair
Kalafatakis, I., & Karagogeos, D. (2021) · Biomolecules · doi:10.3390/biom11071058 · Cited by 108
“A number of factors have been described as possible underlying reasons for limited myelin repair over the course of disease; among them, OPC numbers may be decreased [31,32].”
BackgroundMechanisms of damage to myelin and oligodendrocytes and their relevance to disease
Merrill, & Scolding (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00200.x · Cited by 111
Maeda, Y., Solanky, M., Menonna, J., Chapin, J., Li, W., & Dowling, P. (2001) · Annals of Neurology · doi:10.1002/ana.1015 · Cited by 111
Niehaus, A., Shi, J., Grzenkowski, M., Diers-Fenger, M., Archelos, J., Hartung, H.-P., Toyka, K., Brück, W., & Trotter, J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3<362::aid-ana11>3.0.co;2-6 · Cited by 109
Mader, I., Seeger, U., Weissert, R., Klose, U., Naegele, T., Melms, A., & Grodd, W. (2001) · Brain · doi:10.1093/brain/124.5.953 · Cited by 116
“AJNR Am Jby oligodendrocytes (Prineas et al., 1993).”
Paintlia, M. K., Paintlia, A. S., Singh, A. K., & Singh, I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07136.x · Cited by 108
“A typical feature of CNS demyelinating diseases such as multiple sclerosis (MS) is the recurrence of inflammatory attacks that lead to oligodendrocyte (OL) loss which causes axonal loss and subsequent neurological disabilities in affected individuals (Prineas et al. 1993).”
BackgroundEarly structural changes in acute MS lesions assessed by serial magnetization transfer studies
Dousset, V., Gayou, A., Brochet, B., & Caille, J.-M. (1998) · Neurology · doi:10.1212/wnl.51.4.1150 · Cited by 109
Paintlia, A. S., Paintlia, M. K., Khan, M., Vollmer, T., Singh, A. K., & Singh, I. (2005) · The FASEB Journal · doi:10.1096/fj.05-3861com · Cited by 107
Omari, K. M., Lutz, S. E., Santambrogio, L., Lira, S. A., & Raine, C. S. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080350 · Cited by 111
Review: Glial lineages and myelination in the central nervous system
COMPSTON, A., ZAJICEK, J., SUSSMAN, J., WEBB, A., HALL, G., MUIR, D., SHAW, C., WOOD, A., & SCOLDING, N. (1997) · Journal of Anatomy · doi:10.1046/j.1469-7580.1997.19020161.x · Cited by 104
Karamita, M., Barnum, C., Möbius, W., Tansey, M. G., Szymkowski, D. E., Lassmann, H., & Probert, L. (2017) · JCI Insight · doi:10.1172/jci.insight.87455 · Cited by 102
Axon‐oligodendrocyte interactions during developmental myelination, demyelination and repair
Piaton, G., Gould, R. M., & Lubetzki, C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06831.x · Cited by 102
“It is now clear that repair by remyelination is a common feature of MS (Prineas and Connell 1979; Prineas et al. 1984, 1993; Raine and Wu 1993; Lassmann et al. 1997).”
BackgroundMerson, T. D., Binder, M. D., & Kilpatrick, T. J. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8112-z · Cited by 84
“…processes, MS is also char- acterized by a spontaneous regenerative response that results in partial remyelination of denuded axons, a process identified in both acute and chronic active MS plaques (Prineas et al. 1989, 1993; Lassmann et al. 1997; Patrikios et al. 2006; Patani et al. 2007).”
BackgroundMultiple Sclerosis: Inflammatory and Neuroglial Aspects
Papiri, G., D’Andreamatteo, G., Cacchiò, G., Alia, S., Silvestrini, M., Paci, C., Luzzi, S., & Vignini, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020094 · Cited by 120
The Pathologic Substrate of Magnetic Resonance Alterations in Multiple Sclerosis
Lassmann, H. (2008) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2008.06.005 · Cited by 106
Multiple Sclerosis and Glutamate
GROOM, A. J., SMITH, T., & TURSKI, L. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07533.x · Cited by 98
Gregersen, R., Christensen, T., Lehrmann, E., Diemer, N. H., & Finsen, B. R. (2001) · Experimental Brain Research · doi:10.1007/s002210100715 · Cited by 97
The involvement of mitochondria in the pathogenesis of multiple sclerosis
Kálmán, B., Laitinen, K., & Komoly, S. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.03.020 · Cited by 102
TOTOIU, M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.028 · Cited by 94
“Yajima and Suzuki, 1979) and occurs spontaneously in naturally occurring demyelinating diseases such as MS (Prineas et al., 1993a).”
BackgroundPolarization of macrophages and microglia in inflammatory demyelination
Cao, L., & He, C. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1324-0 · Cited by 104
Linden, J. R., Ma, Y., Zhao, B., Harris, J. M., Rumah, K. R., Schaeren-Wiemers, N., & Vartanian, T. (2015) · mBio · doi:10.1128/mbio.02513-14 · Cited by 93
Scolding, N. J., Rayner-Matthews, P. J., & Compston, D. A. S. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00548-x · Cited by 99
Boulanger, J. J., & Messier, C. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.03.063 · Cited by 108
“However, remyelination is often incomplete or inefficient and chronically demyelinated lesions eventually fail to remyelinate (Prineas et al., 1993, Gensert and Goldman, 1997, Wolswijk, 1998, Franklin, 2002, Patrikios et al., 2006, Goldschmidt et al., 2009).”
Giusto, E., Donegà, M., Cossetti, C., & Pluchino, S. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.009 · Cited by 100
“Most of the demyelinated regions undergo partial remyelination and show structural repair and recovery of function (Barkhof et al., 2003; Chang et al., 2002; Compston, 1996, 1997; Prineas et al., 1993; Raine and Wu, 1993).”
BackgroundFranklin, R. J. M. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00765-1 · Cited by 88
Mader, I., Roser, W., Kappos, L., Hagberg, G. E., Seelig, J., Radue, E. W., & Steinbrich, W. (2000) · PubMed Central · Cited by 87
Regulation of remyelination in multiple sclerosis
Hanafy, K. A., & Sloane, J. A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.048 · Cited by 86
The pathology of multiple sclerosis: a historical perspective1Supported in part by award NS 27321.1
Hickey, W. F. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00079-x · Cited by 88
Concentric sclerosis (Baló): Morphometric and in situ hybridization study of lesions in six patients
Yao, D., Webster, H. D., Hudson, L. D., Brenner, M., Liu, D., Escobar, A. I., & Komoly, S. (1994) · Annals of Neurology · doi:10.1002/ana.410350105 · Cited by 85
Imitola, J., Chitnis, T., & Khoury, S. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.25 · Cited by 83
Cortical remyelination is heterogeneous in multiple sclerosis
Strijbis, E. M. M., Kooi, E.-J., van der Valk, P., & Geurts, J. J. G. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx023 · Cited by 82
Frohman, E. M., Havrdová, E., LUBLIN, F. D., Barkhof, F., Achiron, A., Sharief, M. K., Stüve, O., Racke, M. K., Steinman, L., Weiner, H. L., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.614 · Cited by 85
Soldán, M. M. P., Warrington, A. E., Bieber, A. J., Ćirić, B., Keulen, V. P. V., Pease, L. R., & Rodriguez, M. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(02)00018-0 · Cited by 81
Perspectives on multiple sclerosis.
Grossman, R. I., & McGowan, J. C. (1998) · PubMed · Cited by 93
Identification of glial cell proliferation in early multiple sclerosis lesions
Schönrock, Kuhlmann, Adler, Bitsch, & Brück (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00131.x · Cited by 81
Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells
Baaklini, C. S., Rawji, K. S., Duncan, G. J., Ho, M. F. S., & Plemel, J. R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00225 · Cited by 79
“However, for those with MS, remyelination is variable and prone to failure (Prineas et al., 1993; Patrikios et al., 2006; Patani et al., 2007; Bramow et al., 2010), especially in the context of aging which is known to slow the rate of remyelination (Shields et al., 1999; Goldschmidt et al., 2009;…”
BackgroundHöftberger, R., Fink, S., Aboul‐Enein, F., Botond, G., Olah, J., Berki, T., Ovadi, J., Lassmann, H., Budka, H., & Kovacs, G. G. (2010) · Glia · doi:10.1002/glia.21054 · Cited by 79
“Self-repair mechanisms in MS include remyelination with variable extent (Blakemore, 1974; Prineas et al., 1993).”
BackgroundAra, J., See, J., Mamontov, P., Hahn, A., Bannerman, P., Pleasure, D., & Grinspan, J. B. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21462 · Cited by 79
“Although CNS remyelination occurs in many acute plaques of multiple sclerosis (Prineas and Connell, 1979; Prineas et al., 1993b; Lassmann et al., 1997), failure to remyelinate is a pathological characteristic of many chronic MS lesions (Prineas et al., 1993a).”
BackgroundBrain atrophy in multiple sclerosis: what we know and would like to know
Simon, J. H. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070823 · Cited by 89
Glutamate Receptors in Neuroinflammatory Demyelinating Disease
Bolton, C., & Paul, C. (2006) · Mediators of Inflammation · doi:10.1155/mi/2006/93684 · Cited by 78
Macrophages in CNS remyelination: friend or foe?
Diemel, L. T., Copelman, C. A., & Cuzner, M. L. (1998) · Neurochemical Research · doi:10.1023/a:1022405516630 · Cited by 78
Pu, A., Stephenson, E. L., & Yong, V. W. (2018) · Glia · doi:10.1002/glia.23333 · Cited by 76
SeXX Matters in Multiple Sclerosis
Gilli, F., DiSano, K. D., & Pachner, A. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00616 · Cited by 84
IL-11 Regulates Autoimmune Demyelination
Gurfein, B. T., Zhang, Y., López, C. B., Argaw, A. T., Zameer, A., Moran, T. M., & John, G. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900622 · Cited by 77
Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
Thomas, L., & Pasquini, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00297 · Cited by 76
“This process has been described in animal models and in human demyelinating diseases such as MS (Prineas et al., 1993; Patrikios et al., 2006; Patani et al., 2007).”
Backgroundda Silva, C. J., da Rocha, A. J., Mendes, M. F., Maia, A. C., Braga, F. T., & Tilbery, C. P. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1186oa · Cited by 76
Measuring longitudinal myelin water fraction in new multiple sclerosis lesions
Vargas, W. S., Monohan, E., Pandya, S., Raj, A., Vartanian, T. K., Nguyen, T. D., Rúa, S. M. H., & Gauthier, S. A. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.09.003 · Cited by 79
“…some of the change in Gd+ lesions is due to myelin repair, given that pathological studies showed that remyelination increases dramatically after the onset of demyelination in acute lesions (Prineas et al., 1993; Raine and Wu, 1993) and is consistent with previous MTR studies (Chen et al., 2008).”
Steroid Protection in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis
Garay, L. I., Deniselle, M. C. G., Gierman, L. M., Meyer, M., Lima, A. E., Roig, P., & Nicola, A. F. D. (2008) · NeuroImmunoModulation · doi:10.1159/000135627 · Cited by 82
Neurophysiological evidence for long-term repair of MS lesions: implications for axon protection
Jones, S., & Brusa, A. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00428-8 · Cited by 74
Neuregulin: An Oligodendrocyte Growth Factor Absent in Active Multiple Sclerosis Lesions
Viehover, A., Miller, R. H., Park, S.-K., Fischbach, G., & Vartanian, T. (2001) · Developmental Neuroscience · doi:10.1159/000048721 · Cited by 74
Neuregulin and erbB receptor expression in normal and diseased human white matter
Cannella, B., Pitt, D., Marchionni, M. A., & Raine, C. S. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00201-5 · Cited by 80
Glial cells as targets and producers of neurotrophins
Althaus, H. H., & Richter‐Landsberg, C. (2000) · International review of cytology · doi:10.1016/s0074-7696(00)97005-0 · Cited by 80
Multiple Sclerosis: Microglia, Monocytes, and Macrophage-Mediated Demyelination
Prineas, J. W., & Parratt, J. D. E. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab083 · Cited by 83
Self-citationFranklin, R. J. M., Gilson, J. M., Franceschini, I. A., & Barnett, S. C. (1996) · Glia · doi:10.1002/(sici)1098-1136(199607)17:3<217::aid-glia4>3.0.co;2-y · Cited by 305
Cannella, B., Pitt, D., Capello, E., & Raine, C. S. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64606-8 · Cited by 78
Microglia Diversity in Health and Multiple Sclerosis
Zia, S., Rawji, K. S., Michaels, N. J., Burr, M., Kerr, B. J., Healy, L. M., & Plemel, J. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588021 · Cited by 70
Filippi, M., Campi, A., Mammì, S., Martinelli, V., Locatelli, T., Scotti, G., Amadio, S., Canal, N., & Comi, G. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.58.1.31 · Cited by 72
Tourbah, A., Linnington, C., Bachelin, C., Avellana-Adalid, V., Wekerle, H., & Baron-Van Evercooren, A. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19971201)50:5<853::aid-jnr21>3.0.co;2-0 · Cited by 70
“Initially, the effects of this immune insult to the CNS are potentially reversible as demonstrated by the observation that remyelination is common in early MS lesions (Lassman, 1983; Prineas et al., 1993).”
BackgroundPsenicka, M. W., Smith, B. C., Tinkey, R. A., & Williams, J. L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.654284 · Cited by 75
“However, despite the inflammatory nature of active lesions, oligodendrocytes often reappear during early stages of remyelination in acute MS, contributing to partial or complete recovery (Lassmann, 1983; Prineas et al., 1993; Raine and Wu, 1993; Lucchinetti et al., 1999, 2000; Barkhof et al., 2003; Patrikios et al., 2…”
BackgroundIn Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination
Merrill, J. E. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.145 · Cited by 69
“…has been well documented that these cells are activated by the CNS pathology in MS to migrate to the lesion sites and attempt to repair the damage by differentiating and remyelinating naked axons (Prineas and Connell, 1979; Prineas et al, 1984, 1989, 1993; Raine and Wu, 1993; Lassmann et al, 1997).”
BackgroundInsulin‐like growth factors and binding proteins in multiple sclerosis plaques
Gveric, Cuzner, M. L., & Newcombe, J. (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00187.x · Cited by 68
McDonald, W. I., Miller, D. H., & Thompson, A. J. (1994) · Annals of Neurology · doi:10.1002/ana.410360106 · Cited by 74
Mechanisms of action of interferon-? in multiple sclerosis
Arnason, B. G. W., Dayal, A. S., Qu, Z. X., Jensen, M. A., Gen�, K., & Reder, A. T. (1996) · Springer Seminars in Immunopathology · doi:10.1007/bf00792613 · Cited by 74
Fok‐Seang, J., DiProspero, N. A., Meiners, S., Muir, E., & Fawcett, J. W. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00251.x · Cited by 67
Kira, J., Tobimatsu, S., & Goto, I. (1994) · Internal Medicine · doi:10.2169/internalmedicine.33.82 · Cited by 68
Lindner, M., Thümmler, K., Arthur, A. T., Brunner, S. P., Elliott, C., McElroy, D., Mohan, H., Williams, A., Edgar, J. M., Schuh, C., et al. (2015) · Brain · doi:10.1093/brain/awv102 · Cited by 73
“…of remyelination is not due to an intrinsic defect in cells of the oligodendrocyte lineage as demonstrated by the presence of remyelinated ‘shadow plaques’ in many patients at autopsy (Prineas and Connell, 1979; Prineas et al., 1993; Raine and Wu, 1993; Patrikios et al., 2006; Patani et al., 2007).”
BackgroundChari, D. M., Zhao, C., Kotter, M. R., Blakemore, W. F., & Franklin, R. J. M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20763 · Cited by 66
“Extensive remyelination can occur in demyelinating lesions, including many acute plaques of MS (Prineas and Connell, 1979; Prineas et al., 1993, Lassmann et al., 1997); remyelination restores function lost as a consequence of demye- lination (Smith et al., 1979; Jeffery and Blakemore, 1997) with…”
BackgroundZhang, Y., Zhu, H., Mitchell, J. R., Costello, F., & Metz, L. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.03.075 · Cited by 65
Archelos, J. J., Trotter, J., Previtali, S. C., Weißbrich, B., Toyka, K. V., & Hartung, H. (1998) · Annals of Neurology · doi:10.1002/ana.410430107 · Cited by 66
Smith, K. J. (1994) · Eye · doi:10.1038/eye.1994.51 · Cited by 62
Glial cell transplanatation and remyelination of the central nervous system
Duncan, I. D. (1996) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1996.tb00852.x · Cited by 64
Laron, M., Cheng, H., Zhang, B., Schiffman, J. S., Tang, R. A., & Frishman, L. J. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509359782 · Cited by 64
Stem cells for the treatment of myelin loss
Keirstead, H. S. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.09.008 · Cited by 68
Distinctive Properties of Human Adult Brain-Derived Myelin Progenitor Cells
Ruffini, F., Arbour, N., Blain, M., Olivier, A., & Antel, J. P. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63266-x · Cited by 64
The response of adult oligodendrocyte progenitors to demyelination in EAE
Reynolds, R., di Bello, I. C., Dawson, M. R. L., & Levine, J. M. (2001) · Progress in brain research · doi:10.1016/s0079-6123(01)32073-3 · Cited by 65
Davie, C. A., Silver, N., Barker, G. J., Tofts, P. S., Thompson, A. J., McDonald, W. I., & Miller, D. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.6.710 · Cited by 62
Girolamo, F., Ferrara, G. B., Strippoli, M., Rizzi, M., Errede, M., Trojano, M., Perris, R., Roncali, L., Svelto, M., Mennini, T., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.021 · Cited by 69
“…events, regenerative processes take place inMS and EAE demyelinated lesions ofWM, including attempts by nervous tissue to remyelinate the damaged areas (Albert et al., 2007; Blakemore, 1974; Bunge et al., 1961; Franklin and ffrench-Constant, 2008; Patani et al., 2007; Prineas et al., 1993).”
Metadata
- Authors
- Prineas, J. W., Barnard, R. O., Kwon, E. E., Sharer, L. R., & Cho, E. ‐.
- Affiliations
- East Orange VA Medical Center (US)
- Rutgers New Jersey Medical School (US)
- Corresponding author
- Prineas, J. W.
- ORCID
- Prineas, J. W.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1993-02
- Volume
- 33
- Issue
- 2
- Pages
- 137-151
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2024751716
- Cited by
- 574
- References
- 46
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 19 · 2018: 14 · 2017: 12 · 2016: 10 · 2015: 14 · 2014: 18 · 2013: 13 · 2012: 16
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, remyelination, demyelination, oligodendrocytes, myelin destruction, disease duration, early-onset multiple sclerosis
- MeSH terms
- Adolescent, Adult, Aged, Axons, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Myelin Sheath, Nerve Regeneration, Oligodendroglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.